{
    "nctId": "NCT06007027",
    "briefTitle": "Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors",
    "officialTitle": "Vaginal Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors - A Randomized, Blinded, Placebo-controlled Study",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Genitourinary Syndrome of Menopause",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Vaginal dryness",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer survivor in endocrine therapy\n* Symptomatic genitourinary symdrom of menopause with vaginal discomfort and/or dyspareunia\n* Able to read and understand Danish\n* Able to give written informed consent\n\nExclusion Criteria:\n\n* Pelvic organ prolapse \u2265 stage 2 according to the Pelvic Organ Prolapse Quantification staging system\n* Use of non-hormonal/hormonal vaginal therapies (1 and 12 months prior to the baseline visit, respectively)\n* Use of Chemotherapy (6 months prior to the baseline visit)\n* Acute urinary tract infection or active genital infection\n* History of vaginal reconstructive surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}